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Abstract 
Purpose: To investigate the clinical significance of infection‑related ventilator‑associated complications (IVAC) and 
their impact on carbapenem consumption in mechanically ventilated (MV) patients colonised with extended‑spec‑
trum β‑lactamase‑producing Enterobacteriaceae (ESBLE).
Methods: Inception cohort study from the French prospective multicenter OUTCOMEREA database (17 ICUs,  
1997–2015) including all ESBLE carriers (systematic rectal swabbing at admission then weekly and/or urinary or 
superficial surgical site colonisation) with MV duration > 48 h and ≥ 1 episode of IVAC after carriage documentation. 
All ICU‑acquired infections were microbiologically documented.
Results: The 318 enrolled ESBLE carriers (median age 68 years; males 67%; medical admission 68%; imported car‑
riage 53%) experienced a total of 576 IVAC comprising 361 episodes (63%) without documented infection, 124 (21%) 
related to infections other than ventilator‑associated pneumonia (VAP), 73 (13%) related to non‑ESBLE VAP and 18 
(3%) related to ESBLE VAP. Overall, ESBLE infections accounted for only 43 episodes (7%). Carbapenem exposure within 
the preceding 3 days was the sole independent predictor of ESBLE infection as the causative event of IVAC, with a 
protective effect (adjusted odds ratio 0.2, 95% confidence interval 0.05–0.6; P < 0.01). Carbapenems were initiated in 
9% of IVAC without infection, 15% of IVAC related to non‑VAP infections, 42% of IVAC related to non‑ESBLE VAP, and 
56% of IVAC related to ESBLE VAP (ESBLE VAP versus non‑ESBLE VAP: P = 0.43).
Conclusions: IVAC in ESBLE carriers mostly reflect noninfectious events but act as a strong driver of empirical car‑
bapenem consumption. ESBLE infections are scarce yet hard to predict, strengthening the need for novel diagnostic 
approaches and carbapenem‑sparing alternatives.
Keywords: Extended‑spectrum beta‑lactamase, Mechanical ventilation, Ventilator‑associated pneumonia, 
Carbapenem, Outcome
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Introduction
The prevalence of colonisation with extended-spectrum 
β-lactamase-producing Enterobacteriaceae (ESBLE) has 
reached critical levels in patients admitted to the inten-
sive care unit (ICU) owing to the successful spread of 
these pathogens in both healthcare settings and commu-
nity-based populations [1, 2]. Carriage being the main 
prerequisite for ICU-acquired ESBLE infections [3], cur-
rent guidelines advocate considering the colonisation 
status to heighten the likelihood of adequate empirical 
coverage in patients with suspected nosocomial sepsis 
[4]. Yet, this approach results in an excess consumption 
of carbapenems that could hasten the dissemination of 
carbapenem-resistant Gram-negative bacteria in the hos-
pital environment [5–8], making the prediction of ESBLE 
infections a pivotal component of carbapenem-sparing 
initiatives in identified carriers. This appears especially 
relevant for patients under mechanical ventilation (MV), 
with ventilator-associated pneumonia (VAP) account-
ing for most of suspected and confirmed ICU-acquired 
infections in this population [9, 10].
A novel algorithm for reporting ventilator-associated 
events was issued by the Centers for Disease Control and 
Prevention (CDC) in 2013 [11]. This includes (1) venti-
lator-associated conditions (VAC)—an episode of wors-
ening oxygenation defined by an increase in required 
levels of positive-end expiratory pressure (PEEP) and/or 
 FiO2 for at least two calendar days following a period of 
stability or improvement, (2) infection-related ventila-
tor-associated complications (IVAC)—that is, a subset 
of VAC with systemic inflammatory response elements 
suggestive of a new infection and triggering either the 
initiation of an antimicrobial regimen or the broadening 
of spectrum in patients already receiving antibiotics, and 
(3) VAP, which are defined according to this new clas-
sification as IVAC with clinical and/or microbiological 
arguments for pneumonia, regardless of chest radiograph 
patterns.
Our group and others have previously shown that 
IVAC are common in MV patients and may be associ-
ated with pulmonary or non-pulmonary infections as 
well as a large panel of sepsis-mimicking conditions not 
resulting from an infectious event [12–14]. However, the 
epidemiology and clinical significance of IVAC have not 
been specifically investigated in MV patients colonised 
with ESBLE. In this inception cohort study, we sought to 
appraise the causes of IVAC—with a focus on VAP and 
other ICU-acquired infections due to ESBLE—and their 
impact on carbapenem exposure in a multicentre popula-
tion of critically ill ESBLE carriers.
The results of this work were partly presented at the 
2017 annual conference of the European Society of 
Intensive Care Medicine (Vienna, Austria, 23–27 Sep-
tember 2017, abstract 0944) [15].
Patients and methods
Patient data source: the OUTCOMEREA prospective 
database
This observational study was conducted using a mul-
ticentre longitudinal database fuelled since November 
1996 by 17 ICUs contributing to the OUTCOMEREA 
network. The methodology implemented for data collec-
tion and quality control has been described elsewhere [5]. 
Briefly, a minimum of 50 patients older than 16 years and 
with an ICU stay of more than 24  h are included every 
year by each participating ICU, which may enter into the 
database either all admitted patients or only a subset of 
them following a fixed algorithm that ensures random 
recruitment (e.g. all admissions in predefined rooms in 
a given ICU) (Table S1 in the Electronic Supplementary 
Material, ESM). Data are collected at admission (demo-
graphical characteristics, chronic diseases, admission fea-
tures, baseline severity indexes, admission diagnosis and 
admission type), then exhaustively recorded on a daily 
basis throughout the ICU stay [clinical and biological 
parameters, assessment of organ functions, requirement 
for MV with levels of PEEP and  FiO2, invasive proce-
dures other than MV, fluid challenges, in-hospital trans-
port, iatrogenic events, carriage of multidrug-resistant 
pathogens, ICU-acquired infections, antibiotic exposure, 
length of stay (LOS), final diagnoses of the ICU stay, deci-
sion to withhold or withdraw life-sustaining therapies, 
and vital status at ICU and hospital discharge]. These 
data are prospectively entered into the database by ICU 
staff through an anonymised electronic case report form 
using the Vigirea, Rhea and e-Rhea software (Outcom-
eRea, Rosny-sous-Bois, France). The database protocol 
was submitted to the Institutional Review Board of the 
Clermont-Ferrand University hospital (Clermont-Fer-
rand, France), who waived the need for informed consent 
(IRB no. 5891). The OUTCOMEREA database has been 
registered at the Commission Nationale de l’Informatique 
et des Libertés (registration no. 8999262), in compliance 
with French law on electronic data sources.
Take‑home messages 
IVAC in mechanically ventilated ESBLE carriers mostly reflect non‑
infectious events but act as a strong driver of empirical carbapenem 
consumption.
The lack of reliable predictor of ESBLE infections emphasises the 
need for novel diagnostic approaches and carbapenem‑sparing 
therapeutic alternatives.
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Study population and definitions
Patients admitted between May 1997 and December 
2015 were considered for enrolment in the study cohort. 
We included all ESBLE carriers receiving invasive MV 
for more than 2 days and with no ESBLE VAP before and 
at least one episode of IVAC after the documentation of 
colonisation. Intestinal carriage of ESBLE was universally 
screened in all participating units by rectal swabbing at 
ICU admission and weekly afterwards. ESBLE carriage 
was defined as a positive rectal swab, a positive urine 
culture without evidence of urinary tract infection or 
a positive superficial sample from a surgical wound. Of 
note, colonisation of the lower respiratory tract or the 
normal skin by multidrug-resistant pathogens—includ-
ing ESBLE—is not routinely monitored in ICUs contrib-
uting to the OUTCOMEREA database. ESBLE carriage 
was deemed imported in patients with a first positive 
sample within 48 h following admission and acquired in 
the ICU in cases of negative admission samples. Patients 
were considered colonised from the first positive carriage 
sample to ICU discharge or death.
VAP was diagnosed using standard criteria [16], i.e. 
new or persistent pulmonary infiltrates on chest X-ray 
combined with purulent tracheal secretions and/or 
fever or hypothermia (body temperature greater ≥ 38.5 
or ≤ 36.5  °C, respectively) and/or leukocytosis or leuko-
penia (white blood cells count ≥ 10 × 10.9 or ≤ 4 × 10.9/L, 
respectively). A definite diagnosis of VAP required micro-
biological confirmation by quantitative culture from a 
protected brush [≥ 10.3 colony-forming unit (CFU)/mL], 
plugged telescopic catheter (≥ 10.3 CFU/mL), bronchoal-
veolar lavage fluid (≥ 10.4  CFU/mL), or endotracheal 
aspirate (≥ 10.5  CFU/mL). Other ICU-acquired infec-
tions were diagnosed using standard criteria, with micro-
biological documentation for all cases.
IVAC episodes were retrospectively ascertained 
by applying the CDC’s definition (see ESM) [11]. We 
reviewed each episode to identify those associated with 
VAP, other ICU-acquired infections and non-infectious 
events within 2 calendar days (i.e. from 8:00 a.m. to 8:00 
a.m. the following day) before and after the onset of 
worsening oxygenation, except for transports and fluid 
challenges which were only screened within the 2 preced-
ing days. When two non-VAP-associated IVAC occurred 
within 4  days or less, we only retained the first episode 
for analyses. Also, IVAC episodes occurring within 8 days 
after a VAP-associated IVAC were discarded. Lastly, 
in patients with more than five IVAC, only the first five 
IVAC were considered to exclude very late episodes in 
patients with extremely long MV duration. Selected 
episodes were pooled in four mutually exclusive groups 
according to causative events, namely IVAC without doc-
umented infection (including those only attributable to 
one or more non-infectious sepsis-mimicking events and 
those with no identifiable source of infection), non-VAP 
ICU-acquired infections (involving ESBLE and/or other 
pathogens), non-ESBLE VAP (with or without a concom-
itant non-VAP ESBLE infection), and ESBLE VAP.
Statistical analyses
Data are expressed as median [interquartile range (IQR)] 
for continuous variables and number (%) for categorical 
variables. Patient characteristics were compared using 
the Kruskal–Wallis test for continuous variables and the 
Fisher exact test or χ2 test for categorical variables, as 
appropriate. Exposure to each antimicrobial class before 
and after IVAC episodes was compared across the four 
IVAC groups using the Cochran–Mantel–Haenzel exact 
test for categorical variables and Cochran–Mantel–Hae-
nzel or Wilcoxon non-parametric tests for continuous 
variables, with stratification on episode ranks. For these 
comparisons, β-lactams were pooled according to the 
classification of Weiss et al. [17].
Factors associated with the identification of an ESBLE 
infection (VAP or other than VAP) as the causative event 
of IVAC were first investigated by univariate logistic 
regression analyses using a marginal model, with each 
episode being handled independently (generalised esti-
mating equations accounting for unknown covariance 
structure between distinct episodes in a given patient). 
Variables yielding P values < 0.20 were then entered into 
a multiple logistic regression model for the measurement 
of odds ratios (OR) and 95% confidence intervals (CI), 
with a diagnosis of IVAC related to an ESBLE infection 
as the primary outcome. The same procedure was applied 
to identify factors associated with a diagnosis of ESBLE 
VAP as the causative event in VAP-related episodes of 
IVAC. The Akaike information criterion was used in both 
models to avoid over-fitting. Missing values were handled 
by single imputation.
All statistical analyses were carried out with SAS v.9.4 




We included 318 ESBLE carriers in the study [median 
age, 67.8 (58.4–76.5) years; males, 66.7%; medical 
admission, 67.9%] (Fig.  1; Table  1). ESBLE carriage was 
imported in 169 patients (53.1%) and acquired in the ICU 
after a median ICU LOS of 11 [7–17] days in the remain-
ing 149 patients (46.9%). Escherichia coli (n = 118, 37.1%), 
Klebsiella pneumoniae (n = 70, 22%) and Enterobacter 
spp. (n = 43, 13.5%) accounted for most of the carriage 
isolates of ESBLE. 
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Description of IVAC episodes
A total of 576 episodes of IVAC were analysed. Among 
them, 361 episodes (62.7%) were not attributable to a 
documented ICU-acquired infection, 124 (21.5%) were 
related to one or more non-VAP ICU-acquired infec-
tions, 73 (12.7%) were related to a non-ESBLE VAP, and 
only 18 (3.1%) were related to an ESBLE VAP (Fig.  2; 
Table S2 in the ESM). Two or more underlying events 
were identified in 121 episodes (21%) (Table S2). Over-
all, only 43 episodes of IVAC (7.5%) were associated with 
one or more ICU-acquired ESBLE infections (VAP and/
or infections other than VAP). Non-VAP ESBLE infec-
tions were catheter-related infections with or without 
bloodstream infection (n = 18), non-catheter-related 
bloodstream infections (n = 12) and surgical site infec-
tions (n = 18).
The distribution of IVAC causes—including ESBLE 
infections—was neither significantly influenced by epi-
sode ranking nor by the number of days spent in the 
ICU since admission or carriage documentation (Table 
S2). Likewise, the causes of IVAC were similar between 
patients with imported and ICU-acquired carriage, as 
16,747 ICU patients
admitted between March 6, 





with MV duration > 48h
149 ESBLE carriers not intubated
25 ESBLE carriers with MV duration ≤ 48h
512 ESBLE carriers with
MV duration > 48h and no 
ESBLE VAP before carriage 
documentation
14 ESBLE carriers with ESBLE VAP before 
carriage documentation
225 (70%) ESBLE carriers
without VAP
Number of IVAC: 1 [1 - 2]
20 (7%) ESBLE carriers
with ESBLE VAP
Number of IVAC: 2 [1 - 2]
194 ESBLE carriers with MV duration > 48h 
and no IVAC after carriage documentation
73 (23%) ESBLE carriers
with non-ESBLE VAP 
Number of IVAC: 2 [1 - 3]
36 (19%) ESBLE carriers
with VAP, including 4 (2%) 
with ESBLE VAP
318 ESBLE carriers with MV 
duration > 48h and one or 
more IVAC after carriage 
documentation (study cohort)
Fig. 1 Study flow‑chart. Numbers of IVAC per patient categories are indicated as median [interquartile range]. ICU intensive care unit, ESBLE 
extended‑spectrum β‑lactamase‑producing Enterobacteriaceae, MV mechanical ventilation, IVAC infection‑related ventilator‑associated complica‑
tion, VAP ventilator‑associated pneumonia
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between those colonised with ESBL-producing E. coli 
and other ESBLE species (Tables S3 and S4, respectively).
Predictors of ESBLE infection as the causative event of IVAC
The characteristics of IVAC episodes related to an ESBLE 
infection (pooled, n = 43) are compared to those of other 
episodes (n = 533) in Table S5, with corresponding uni-
variate OR. In the multivariable logistic regression model, 
the sole independent predictor of ESBLE infection was an 
exposure to carbapenems within the 3 days preceding the 
occurrence of IVAC, which exerted a protective effect 
(OR 0.2, 95% CI 0.05–0.6, P < 0.01) (Table 2). This 3-day 
cut-off correlated with the significant variations that we 
observed in the frequency of carbapenem pre-exposure 
across the four IVAC sub-groups on the day preceding 
the occurrence of IVAC (that is, Day 1) but also from Day 
3 to Day 2 before IVAC (Table 3). It is noteworthy that a 
recent exposure to non-anti-pseudomonal third-genera-
tion cephalosporins was not an independent predictor of 
ESBLE infection (Table S6).
A total of 120 VAP were diagnosed in 93 patients, 
including 24 ESBLE VAP (20%) in 20 patients (Table 
S7). In the subset of VAP-related IVAC, no independent 
Table 1 Characteristics of the 318 mechanically ventilated 
ESBLE carriers included in the study
Variable Patients
Age, years 67.8 [58.4–76.5]
Sexe, male 212 (66.7)
Body mass index, kg/m2 25.6 [21.8–28.8]
Chronic diseases
 Respiratory 57 (17.9)
 Cardiac 44 (13.8)
 Hepatic 14 (4.4)
 Renal 23 (7.2)
 Immunosuppression 62 (19.5)
 Diabetes mellitus 66 (20.7)
MacCabe score
 0 164 (51.6)
 1 116 (36.5)
 2 38 (11.9)
Type of ICU stay
 Surgical, scheduled 27 (8.5)
 Surgical, unscheduled 75 (23.6)
 Medical 216 (67.9)
Type of ICU admission
 Direct (from the ED) 126 (39.6)
 Transfer (from wards) 192 (60.4)
 Hospital LOS before ICU admission, days 2 [1–13]
Reason for ICU admission
 Acute respiratory failure 79 (24.8)
 Shock 112 (35.2)
 Coma 43 (13.5)
 Acute renal failure 12 (3.8)
 Multi‑organ failure 20 (6.3)
 Miscellaneous 52 (16.4)
 SOFA score at ICU admission 7 [4–10]
 SAPS II at ICU admission 51 [40–64]
 Type of ESBLE carriage
 Imported 169 (53.1)
 Patients admitted from the ED 71 (22.3)
 Patients transferred from wards 98 (30.8)
 Acquired in the ICU 149 (46.9)
 ICU LOS before carriage acquisition, days 11 [7–17]
Characteristics at the time of ESBLE  colonisationa
 SOFA score 7 [4–10]
 SAPS II 45 [34–55]
 Invasive  MVb 314 (98.7)
 Vasopressors 184 (57.9)
 Arterial line catheter 133 (41.8)
 Central venous catheter 216 (67.9)
 Renal replacement therapy 49 (15.4)
 Urinary catheter 294 (92.4)
 Proton‑pump inhibitor 204 (64.1)
 Enteral nutrition 181 (56.9)
 Parenteral nutrition 91 (28.6)
Table 1 continued
Variable Patients
 Decision to withhold or withdraw life support 17 (5.3)
 Prior CDAD 11 (3.4)
 MRSA carriage 32 (10.1)
 MDRPA carriage 11 (3.5)
 AHE carriage 13 (4.1)
VAP after ESBLE colonisation
 None 225 (70.7)
 Non‑ESBLE VAP 73 (23.0)
 ESBLE VAP 20 (6.3)
Outcome
 MV duration, days 19 [12–33]
 ICU LOS, days 25 [14–42]
 Hospital LOS after ICU discharge, days 35 [22–61]
 Hospital LOS, overall, days 46.5 [26–75]
 In‑ICU death at day 28 58 (18.2)
 In‑ICU death, overall 105 (33.0)
 In‑hospital death, overall 134 (42.1)
Patient data are expressed as number (%) or median [interquartile range]
ESBLE extended-spectrum β-lactamase-producing Enterobacteriaceae, ICU 
intensive care unit, ED emergency department, LOS length of stay, SOFA 
sequential organ failure assessment, SAPS II simplified acute physiology score 
II, MV mechanical ventilation, CDAD Clostridium difficile-associated diarrhoea, 
MRSA methicillin-resistant Staphylococcus aureus, MDRPA multidrug-resistant 
Pseudomonas aeruginosa, AHE AmpC-hyperproducing Enterobacteriaceae, VAP 
ventilator-associated pneumonia
a Defined as the ICU day with the first carriage sample positive for ESBLE (see 
“Patients and methods” for details)
b Four patients were intubated after the documentation of ESBLE carriage
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Fig. 2 Causes of IVAC, proportion of episodes attributable to one or more ICU‑acquired ESBLE infections and initiation of carbapenem therapy in 
mechanically ventilated ESBLE carriers. IVAC infection‑related ventilator‑associated complication, ICU intensive care unit, ESBLE extended‑spectrum 
β‑lactamase‑producing Enterobacteriaceae, VAP ventilator‑associated pneumonia, NS non‑significant. The rates of new carbapenem treatments are 
indicated as measured values and 95% confidence intervals. *P < 0.001 for overall comparison between the four causal groups (no significant differ‑
ence between non‑ESBLE VAP and ESBLE VAP, P = 0.43)
Table 2 Factors associated with an ESBLE infection as the causative event of IVAC: multivariable logistic regression 
model
Variables entered in the multivariable model (first step) were MacCabe score, hospital LOS before ICU admission, SASPS II and SOFA score at ICU admission, one 
or more previous IVAC before the considered episode, ICU LOS before IVAC, hepatic and neurological SOFA scores on the day preceding IVAC, and exposure to 
ureidopenicillins, carboxypenicillins, third-generation cephalosporins, carbapenems, aminoglycosides and metronidazole before IVAC (see Table S5 for the full results 
of univariate analyses)
ESBLE extended-spectrum β-lactamase-producing Enterobacteriaceae, IVAC infection-related ventilator-associated complication, OR odds ratio, CI confidence interval, 
SAPS II simplified acute physiological score II, ICU intensive care unit, 3GC third-generation cephalosporins, LOS length of stay
Variable Adjusted OR [95% CI] P value
MacCabe score 0.13
 0 1 (Ref )
 1 1.7 [0.81–3.72]
 2 3.4 [1.24–9.07]
SAPS II at ICU admission, per point increase 1 [0.98–1.03] 0.55
Glasgow coma scale ≤ 9 at Day 1 before IVAC 0.2 [0.05–1.12] 0.07
ICU LOS before IVAC 0.20
 < 13 days 1 (Ref )
 13–25 days 0.5 [0.22–1.09]
 > 25 days 0.6 [0.26–1.21]
Aminoglycoside exposure from Day 3 to IVAC Day 0.4 [0.12–1.51] 0.11
Ureido‑/carboxy‑penicillin and/or 3GC exposure from Day 3 to IVAC Day 1.6 [0.75–3.36] 0.25
Carbapenem exposure from Day 3 to IVAC Day 0.2 [0.05–0.6] < 0.01
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predictor of ESBLE VAP could be identified by multivari-
able logistic regression analysis (Tables S8 and S9).
Correlation between IVAC and antimicrobial exposure
Overall, a new carbapenem-based antimicrobial regimen 
was started in 94 episodes of IVAC (29.6%) (Table 3). Of 
note, the empirical use of carbapenems was as frequent 
in episodes related to an ESBLE VAP as in those result-
ing from a non-ESBLE VAP (42.5 vs. 55.6%, respectively, 
P = 0.43). By contrast, an antipseudomonal β-lactam 
other than a carbapenem (i.e. either cefepime, ceftazi-
dime, aztreonam, ticarcillin-clavulanate or piperacillin-
tazobactam) was initiated in only 32 episodes of IVAC 
(5.5%) (Table S10).
Outcomes
The proportion of patients who died during the episode 
(overall 18%) and the median subsequent duration of MV 
[overall, 3 (6–10) days] were higher in VAP-related IVAC 
than in those with other causes but were similar for IVAC 
due ESBLE VAP and those due to non-ESBLE VAP (Table 
S11). Overall in-ICU and in-hospital mortality rates were 
33 and 42.1%, respectively (Table 1).
Discussion
In this multicentre cohort of mechanically ventilated 
ESBLE carriers, a restricted proportion of IVAC (7.5%) 
resulted from an ICU-acquired ESBLE infection, with 
Table 3 Associations between IVAC and carbapenem exposure according to causative events in mechanically ventilated 
ESBLE carriers
Data are expressed as number (%) or median [interquartile range]
IVAC infection-related ventilator-associated complication, ESBLE extended-spectrum β-lactamase-producing Enterobacteriaceae, VAP ventilator-associated 
pneumonia
a Including 20 non-VAP ESBLE infections
b Including five episodes with a concomitant non-VAP ESBLE infection
c Global comparison
d ESBLE-VAP versus non-ESBLE VAP comparison









Day 14 to Day 7 before IVAC
 Treated patient 185 (51.2) 50 (40.3) 31 (42.5) 6 (33.3) 0.08/0.69
 Duration, days 1 [0–5] 0 [0–4] 0 [0–5] 0 [0–2] 0.17/0.89
Day 6 to Day 4 before IVAC
 Treated patients 148 (41) 40 (32.3) 24 (32.9) 5 (27.8) 0.19/0.81
 Duration, days 0 [0–3] 0 [0–2] 0 [0–2] 0 [0–1] 0.11/0.74
Day 3 to Day 2 before IVAC
 Treated patients 124 (34.3) 32 (25.8) 17 (23.3) 1 (5.6) 0.01/0/10
 Duration, days 0 [0–2] 0 [0–1] 0 [0–0] 0 [0–0] < 0.01/0.09
Day 1 before IVAC
 Treated patients 103 (28.5) 25 (20.2) 15 (20.5) 0 0.01/0.03
IVAC Day to Day + 3
 Treatment discontinuation 9 (2.5) 1 (0.8) 1 (1.4) 0 < 0.01/1.00
 Treatment continuation 94 (26) 22 (17.7) 12 (16.4) 0 0.01/0.11
 New treatment 34 (9.4) 19 (15.3) 31 (42.5) 10 (55.6) < 0.01/0.43
 Duration, days 0 [0–2] 0 [0–2] 1 [0–3] 1.5 [0–3] < 0.01/0.93
IVAC Day to Day + 7
 Treated patients 125 (34.6) 50 (40.3) 46 (63) 14 (77.8) < 0.01/0.42
 Duration, days 0 [0–2] 0 [0–3] 2 [0–5] 3.5 [1–6] < 0.01/0.30
IVAC Day to Day + 14
 Treated patients 130 (36) 53 (42.7) 47 (64.4) 14 (77.8) < 0.01/0.51
 Duration, days 0 [0–3] 0 [0–4] 2 [0–7] 6 [1–9] < 0.01/0.16
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VAP accounting for only 3.1% of episodes. No independ-
ent predictor of such infections could be identified except 
the protective effect of a recent or concurrent carbap-
enem exposure. Strikingly, the empirical initiation of a 
carbapenem-based regimen was common in IVAC not 
involving ESBLE.
The prevalence of colonisation with ESBLE is rising 
steadily in critically ill patients owing to a continuous 
influx from both community and healthcare ecosystems, 
with carriage rates at admission currently above 10% 
in most of ICUs [18–20]. This results in an increase 
in colonisation pressure that may favour subsequent 
cross-transmission and acquisition during the ICU stay 
[18, 21–23]. Hence, managing an ESBLE carrier with 
a suspicion of nosocomial infection has become a daily 
challenge for many intensivists worldwide. ESBLE infec-
tions are associated with a high likelihood of inadequate 
empirical coverage that translates into lower survival 
rates and extended hospital stays when compared to 
patients infected with broad-spectrum cephalosporins-
susceptible Enterobacteriaceae [5, 24–26]. Yet, while 
negative surveillance samples have a high negative pre-
dictive value for ICU-acquired ESBLE infections, the 
incidence of such infections appears relatively weak in 
documented carriers (that is, from 10 to 25%), includ-
ing in those receiving MV [5, 7, 20, 27, 29]. In this work, 
we attempted an original approach by investigating the 
clinical significance of IVAC rather than focussing on 
documented infections in this population. Albeit the 
accuracy of IVAC as a screening step for VAP remains 
controversial [16, 28], its definition that combines wors-
ening oxygenation and systemic signs suggestive of a new 
infection depicts a pragmatic and frequent situation in 
intubated patients. Our findings indicate that, similarly to 
what has been reported in the general population of MV 
patients [12, 13], the occurrence of IVAC in ESBLE carri-
ers correlates with a wide range of healthcare-associated 
infections as well as non-infectious events, and exerts a 
cause-dependent prognostic impact, VAP-related IVAC 
being associated with a worst outcome in terms of sub-
sequent MV duration and short-term mortality than 
other episodes. More importantly, IVAC secondary to 
an ESBLE infection were scarce, while most VAP-related 
episodes implicated pathogens other than ESBLE. These 
data shed light on the complexity of rationalising the 
empirical use of carbapenems in ventilated ESBLE carri-
ers when a condition compatible with VAP arises.
Predicting ESBLE infections is pivotal for the fine-tun-
ing of initial therapy in known carriers. The few single-
centre studies that addressed this issue yielded conflicting 
results, notably on the prognostic weight of ESBLE spe-
cies or prior antimicrobial use [7, 29]. In the present 
cohort, a carbapenem exposure during the 3 preceding 
days was the sole feature independently associated with 
an ESBLE infection as the underlying event of IVAC, with 
an expected protective effect. We failed to demonstrate 
any significant association with other potential relevant 
predictors such as episode rank, invasive procedures, 
recent exposure to non-carbapenem antimicrobials 
[particularly β-lactam/β-lactamase inhibitor (BL–BLI) 
combinations and fluoroquinolones], colonisation with 
ESBL-producing E. coli versus other ESBLE or imported 
versus ICU-acquired carriage. Likewise, no independent 
relationship could be identified when tracking risk fac-
tors for ESBLE VAP in the subset of VAP-related IVAC. 
Thus, no reliable algorithm could be proposed to exclude 
an ESBLE infection and help restraining the empirical 
use of carbapenems when IVAC occurs in a documented 
carrier not recently exposed to this antimicrobial class.
Carbapenems remain the first-line regimen when a 
severe ESBLE infection is suspected [1, 4, 8]. Here, we 
observed that these agents were routinely introduced 
during IVAC not related to an ESBLE infection, especially 
non-ESBLE VAP. This excessive empirical consumption 
could lead to deleterious ecological side effects and pro-
mote the dissemination of carbapenem-resistant Gram-
negative pathogens, at the carrier level as at the hospital 
scale [6, 7, 30]. Various antimicrobial stewardship initia-
tives may contribute to reduce the use of these antibiot-
ics. Rapid diagnostic tools, such as direct susceptibility 
testing or point-of-care molecular assays on clinical sam-
ples, stand as promising strategies to narrow the empiri-
cal spectrum or allow earlier de-escalation in colonised 
patients [31–33]. Also, a link between the faecal rela-
tive abundance of ESBLE and the hazard of subsequent 
infection has been described in non-ICU patients and 
warrants further investigations in the specific context 
of critical illness [34]. In addition, efforts have recently 
been made to assess the safety of certain BL–BLI com-
binations as carbapenem-sparing alternatives for both 
the empirical and definite therapy of ESBLE infections 
[35]. Evidence has notably emerged to support a role for 
piperacillin-tazobactam provided that pharmacokinetic 
parameters are optimised with high-dose regimen and 
continuous or extended infusion [36, 37]. However, in our 
work, a recent piperacillin-tazobactam exposure did not 
protect carriers from ESBLE infections, including VAP. 
Convincing data are still lacking to appraise the yield of 
this combination for the initial therapy of severe ESBLE 
pneumonia [38]. Along this line, new BL–BLI combina-
tions such as ceftolozane-tazobactam and ceftazidime-
avibactam have been mainly evaluated in the treatment 
of complicated UTI or intra-abdominal infections but 
currently emerge as potential options for the treatment 
of hospital-acquired pneumonia due to ESBLE, including 
VAP [39, 40].
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Strengths of this study include its multicentre design 
that minimises the potential influence of local outbreaks 
on our results, the large number of included patients, the 
exploitation of prospectively collected data and the use 
of accurate statistical methods to address its endpoints. 
Our work also has limitations that deserve to be under-
lined. First, we did not address the ecological impact of 
carbapenem misuse in IVAC unrelated to ESBLE infec-
tions. Second, the empirical regimens initiated during 
IVAC were not compared to those of a matched cohort of 
MV patients not colonised with ESBLE. Third, we did not 
investigate the potential impact of lower airways coloni-
sation with ESBLE on the causes of IVAC since respira-
tory surveillance cultures were not routinely performed 
in participating ICUs. Fourth, all ICU-acquired infections 
were microbiologically documented, with strict applica-
tion of validated culture thresholds for the diagnosis of 
VAP. Hence, we cannot firmly exclude that certain IVAC 
related to ICU-acquired infections were misclassified as 
not resulting from an infectious event in patients already 
receiving appropriate antimicrobial therapy when micro-
biological samples were collected, thereby over-estimat-
ing the protective effect of carbapenem pre-exposure 
regarding ESBLE infections. Lastly, it remains to be con-
firmed whether our results may be extrapolated to other 
critical care environments with distinct colonisation pat-
terns, policies for empirical antimicrobial use and pro-
portion of surgical patients.
In conclusion, the occurrence of IVAC in ESBLE car-
riers acts as a strong driver of empirical carbapenem use 
although most of episodes reflect events not resulting 
from a documented infection and are unrelated to the 
colonisation status. ESBLE infections appear scarce yet 
hardly predictable using standard clinical criteria. This 
study emphasises the global need for novel diagnostic 
approaches and the validation of carbapenem-sparing 
empirical regimen in this patient population.
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